Related Experiment Video
Updated: Sep 25, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Regulation and role of CAMKK2 in prostate cancer
Thomas L Pulliam1,2,3, Pavithr Goli1,4, Dominik Awad1,5
1Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
In 2011, CAMKK2, the gene encoding calcium/calmodulin-dependent kinase kinase 2 (CAMKK2), was demonstrated to be a direct target of the androgen receptor and a driver of prostate cancer progression. Results from multiple independent studies have confirmed these findings and demonstrated the potential role of CAMKK2 as a clinical biomarker and therapeutic target in advanced prostate cancer using a variety of preclinical models. Drug development efforts targeting CAMKK2 have begun accordingly. CAMKK2 regulation can vary across disease stages, which might have important implications in the use of CAMKK2 as a biomarker. Moreover, new non-cell-autonomous roles for CAMKK2 that could affect tumorigenesis, metastasis and possible comorbidities linked to disease and treatment have emerged and could present novel treatment opportunities for prostate cancer.
Insights
Calcium/calmodulin-dependent kinase kinase 2 (CAMKK2) drives prostate cancer progression and is a therapeutic target. Further research into CAMKK2
Area of Science:
- Urology
- Oncology
- Molecular Biology
Background:
- The gene CAMKK2, encoding calcium/calmodulin-dependent kinase kinase 2, was identified in 2011 as an androgen receptor target and a driver of prostate cancer.
- Multiple studies confirm CAMKK2's role in advanced prostate cancer, supporting its potential as a biomarker and therapeutic target.
Purpose of the Study:
- To review the established and emerging roles of CAMKK2 in prostate cancer.
- To discuss implications for biomarker development and therapeutic strategies.
Main Methods:
- Review of preclinical models and independent study findings.
- Analysis of CAMKK2 regulation across disease stages.
- Exploration of non-cell-autonomous functions.
Main Results:
- CAMKK2 is a validated target in advanced prostate cancer.
- CAMKK2 regulation varies with disease stage, impacting biomarker utility.
- Emerging non-cell-autonomous roles suggest new therapeutic avenues.
Conclusions:
- CAMKK2 remains a significant target for prostate cancer therapy and biomarker development.
- Understanding CAMKK2's complex roles, including non-cell-autonomous functions, is crucial for advancing treatment strategies.
More Related Videos
Related Concept Videos
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
cAMP-dependent Protein Kinase Pathways
MAPK Signaling Cascades
Inhibition of Cdk Activity
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

